FOLLOW US

Endocrine Research Updates

For Medical Professionals

Doctors should be monitoring patients for risks of chronic kidney disease.
Assessment tool now available to enable clinicians to identify patients with an increased likelihood of developing chronic kidney disease so that preventive measures may be initiated.
People who require insulin will welcome the advent of insulin biosimilars.
Recent regulatory actions clear path for development of insulin biosimilars, expands indications for Pure EPA, and fast paces first possible treatment for end-stage liver disease (NASH).
Diabetes patients who complain of joint pain should be heeded as a sign of gout.
Treating patients at risk for or diagnosed with type 2 diabetes should be closely monitored for gout-related disease, with treat-to-target therapy initiated early with ongoing monitoring, informed by new consensus statement, and clinical guidelines pending from the American College of Rheumatology.
Stem cell therapy is poised to bypass issues of transplant rejection.
Stem cell transplantation holds ever greater potential for improving glucose control in patients with type 1 diabetes; however, these same patients also face increased morbidity and mortality for cardiovascular disease, an ongoing hurdle.
Advances in stem cell transplantation may replace the need for insulin in type 1 diabetes and may lead to repair of damaged heart tissue following a heart attack.
Will weight loss or good blood sugar control improve type 2 diabetes.
Two leading experts debate the evidence and explore the benefits of initiating a blood glucose-directed or obesity-centric management treatment plan, pointing out the strengths in choosing one disease approach over the other.
Experts propose a stepwise approach to diagnosing possible statin intolerance and achieving optimal cholesterol-lowering management in patients with hyperlipidemia who have had poor medication compliance despite their increased risk of both CVD and often type 2 diabetes.
Patients with diabetes must be treated carefully to avoid common complications.
Expert panel addresses barriers to and advancements in achieving optimal hyperkalemia management aiming to improve outcomes regarding kidney disease and cardiovascular events in in patients with diabetes.
Study finds ticagrelor plus aspirin more effective in reducing ischemic cardiovascular events in patients with type 2 diabetes provided there is no heightened concern for excessive bleeding.
Hypertension is one of 5 key factors that indicate risk for metabolic syndrome.
Given the effectiveness of available interventions, the Endocrine Society issues a practice guideline to prompt proactive efforts at screening for the metabolic components leading to cardiovascular disease and type 2 Diabetes.
Malignancy of thyroid nodules can be informed by genetic variability.
Relying on molecular "rule-in" testing of thyroid nodules to better assess for cancer risk will depend upon individual variants which vary in their positive predictive value, according to results of a systematic review of the literature.
Older women at risk of bone loss should be treated cautiously with statins.
Benefit or detriment—New study raises potential adverse effects of statin therapy on bone health in patients with comorbid heart disease and osteoporosis. There are other complications necessitating specific considerations when prescribing statins in women at different ages and stages.
In seniors with diabetes, common disease complications respond well with SGLT2i
The latest study findings on the safety and efficacy of the SGLT-2i, ertugliflozin, offer strong assurance for use in managing diabetes in individuals at 65 years plus, and in others, without concerns for adverse effects on renal function.
Since up to 30% of patients with cancer experience insomnia, even years later, a team from Dana Farbar Cancer Institute has developed a stepwise approach to improve sleep and designed for ease of implementation in any practice setting.
Advances promise preservative-free, fast-acting inhaled insulin for diabetes.
Next Generation Soft-Mist Inhaled human Insulin and GLP-1RA are advancing for treatment of diabetes, and other hormone therapies are just beginning development.
Diabetes distress arises in patients overwhelmed with a chronic disease.
This often unrecognized response arises when individuals are overwhelmed when facing the responsibility of managing a chronic life-long disease. Thus, regular screening should become a routine aspect of diabetes patient care.
Heart failure and renal disease must be treated as a complication of diabetes.
Insights on FDA approvals, side effects of pain meds, and key study findings presented at the European Association for the Study of Diabetes annual meeting,
Patients with Cushing's disease should be monitored for diabetes.
Finally, a long-lasting, monthly injection of pasireotide promotes normalized urinary free cortisol levels and a shrinking or arresting of tumor growth in patients with Cushing’s disease.
GLP-1RAs offer excellent benefits for cardiovascular diabetes.
A new meta-analysis affirms improvements in cardiovascular, kidney and overall outcomes in patients given a GLP-1RA versus SGLT2i for management of type 2 diabetes. Even in those without established cardiovascular disease, significant benefits are achieved with glucagon-like peptide-1 receptor agonists.
Testosterone levels increase risk of nonalcoholic fatty liver disease.
Study findings suggest that elevated levels of androgens even in younger women may offer a clue to patients at increased risk of developing nonalcoholic fatty liver disease.
Diabetic gastroparesis affects one-third of those with long-term diabetes.
A new surgical procedure, a promising minimally invasive, endoscopic device, and new uses for established drugs offer relief from gastrointestinal symptoms of this common complication of diabetes.
close X
SHOW MAIN MENU
SHOW SUB MENU